PERSPECTIVES OF CLINICAL EXPERTS ON THE CURRENT USAGE PATTERNS AND THE PREFERENCE OF VILDAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES
DOI:
https://doi.org/10.22159/ijms.2024.v12i2.50211Keywords:
diabetes, oral antidiabetics, vildagliptin, glycemic controlAbstract
Objective: Although the efficacy and safety of vildagliptin have been proven in randomized clinical trials, data regarding the improved and up-to-date understanding on the management of Type 2 diabetes mellitus from the context of Indian diabetic patients, are scarce. This study was conducted to assess the opinions of clinical experts on the current usage patterns of vildagliptin in the management of Type 2 diabetes among Indian patients.
Methods: A cross-sectional, questionnaire-based study was conducted to collect opinion among physicians in endocrinology across India between June 2022 and December 2022. Convenient sampling method was used. Descriptive statistics were used to summarize the characteristics of the study by employing frequencies and percentages.
Results: It was observed that 95 out of 188 clinicians preferred dipeptidyl peptidase-4 (DPP4) inhibitors (DPP4i) and only 35 out of 188 clinicians (18.6%) opted a combination of Metformin and DPP4 inhibitors as the first hypoglycemic agent for newly detected diabetes. In addition, 141 out of 188 (75%) prescribed vildagliptin only as their preferred drug in the class of DPP4 inhibitors. Further, the reason behind such a high-yielding response for vildagliptin among clinicians and their patients, was its weight-neutral property primarily and posing a low risk of adverse effects. Nearly, half of the clinicians reported a 0.6–1% drop in glycosylated hemoglobin (HbA1c) levels in patients within 3 months of vildagliptin use.
Conclusion: This study concluded that the majority of the specialists preferred using vildagliptin among other DPP4 inhibitors and pointed out that vildagliptin lowered HbA1c within 3 months of use.
References
Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol 2021;69:2932-8.
Berger JP, SinhaRoy R, Pocai A, Kelly TM, Scapin G, Gao YD, et al. A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice. Endocrinol Diabetes Metab 2018;1:e00002.
Halimi S, Schweizer A, Minic B, Foley J, Dejager S. Combination treatment in the management of type 2 diabetes: Focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag 2008;4:481-92.
Bosi E, Camisasca R, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-5.
Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008;10:1047-56.
Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H, et al. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2009;83:233-40.
Kim KS, Oh HJ, Kim JW, Lee YK, Kim SK, Park SW, et al. The clinical characteristics of the newly diagnosed early onset (< 40 years old) diabetes in outpatients’ clinic. Korean Diabetes J 2010;34:119-25.
Khan MA, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health 2020;10:107-11.
Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark Insights 2016;11:95-104.
Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: A 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009;11:804-12.
Halimi S, Raccah D, Schweizer A, Dejager S. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly. Curr Med Res Opin 2010;26:1647-56.
Ji LN, Pan CY, Lu JM, Li H, Zhu DL, Li Q, et al. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: A randomized, open-label, prospective study (VISION). Diabetes Obes Metab 2016;18:775-82.
Pan C, Wang X. Profile of vildagliptin in type 2 diabetes: Efficacy, safety, and patient acceptability. Ther Clin Risk Manag 2013;9:247-57.
Odawara M, Sagara R. Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: Insights from long-term clinical studies in Japan. J Diabetes Metab Disord 2016;15:21.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Manjula S, KRISHNA KUMAR M
This work is licensed under a Creative Commons Attribution 4.0 International License.